New Warning for “Low T” Therapy Involves VTE Risks
The FDA announced in January that it is looking at the possible link between testosterone therapy and increased risks of stroke, heart attack, and death. Yet the agency insists its latest mandate for a label change is unrelated.
What prompted the FDA to revise guidance on the risk of venous thromboembolism (VTE) with “Low T” therapy?